AR043551A1 - Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbomoil]cicloalquil) propanoico como inhibidores de nep, composicion farmaceutica que lo comprende y usos - Google Patents
Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbomoil]cicloalquil) propanoico como inhibidores de nep, composicion farmaceutica que lo comprende y usosInfo
- Publication number
- AR043551A1 AR043551A1 ARP040100785A ARP040100785A AR043551A1 AR 043551 A1 AR043551 A1 AR 043551A1 AR P040100785 A ARP040100785 A AR P040100785A AR P040100785 A ARP040100785 A AR P040100785A AR 043551 A1 AR043551 A1 AR 043551A1
- Authority
- AR
- Argentina
- Prior art keywords
- hypertension
- disorder
- male
- sexual
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
Abstract
Se refiere a inhibidores de la enzima endopeptidasa neutra (NEP), a sus usos, a procedimientos para la preparación de los mismos, a intermediarios usados en la preparación de los mismos y las composiciones que contienen dichos inhibidores. Estos inhibidores tienen utilidad en varias áreas terapéuticas incluyendo el tratamiento de la disfunción sexual masculina y femenina, particularmente de la disfunción sexual femenina (FSD), especialmente cuando la FSD es un trastorno de excitación sexual femenina (FSAD). Reivindicación 1: Un compuesto de fórmula (1), caracterizado porque: R1 es H o CH3; R2 alquilo C1-2; y n es 1 ó 2; un tautómero del mismo o una sal, solvato o polimorfo farmacéuticamente aceptable de dicho compuesto o tautómero. Reivindicación 12: Un compuesto de acuerdo con la reivindicación 9, un procedimiento de acuerdo con la reivindicación 10 o un uso de acuerdo con la reivindicación 11, caracterizado porque el trastorno o afección se selecciona entre hipertensión, hipertensión esencial, hipertensión pulmonar, hipertensión secundaria, hipertensión sistólica aislada, hipertensión asociada con diabetes, hipertensión asociada con aterosclerosis e hipertensión renovascular, enfermedad vascular periférica, insuficiencia cardíaca, angina, insuficiencia renal, insuficiencia renal aguda, edema cíclico, enfermedad de Meniéres, hiperaldosteromismo (primario y secundario) hipercalciuria, apoplejía, glaucoma, obesidad, enfermedades metabólica, Síndrome Metabólico, diabetes, alteración de la tolerancia a la glucosa, retinopatía diabética, neuropatía diabética, trastornos menstruales, parto prematuro, pre-eclampsia, endometriosis y trastornos reproductivos, infertilidad masculina y femenina, síndrome de ovario poliquístico, rechazo al implante, asma, inflamación, leucemia, dolor, dolor por cáncer, depresión, abuso de fármacos, cirrosis, epilepsia, trastornos afectivos, demencia y confusión geriátrica, trastornos gastrointestinales, diarrea, síndrome del intestino irritable, curación de heridas, úlceras diabéticas y venosas y úlceras por presión, choque séptico, secreción de ácido gástrico, hiperreninemia, fibrosis quística, reestenosis, aterosclerosis, disfunción sexual femenina (FSD), trastorno de excitación sexual, trastorno de excitación sexual en mujeres (FSAD), disfunción sexual masculina (MSD), disfunción eréctil masculina (MED), trastorno del deseo sexual hipoactivo, trastorno orgásmico y trastorno por dolor sexual.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0305916A GB0305916D0 (en) | 2003-03-14 | 2003-03-14 | New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors |
| GB0329143A GB0329143D0 (en) | 2003-12-16 | 2003-12-16 | Novel pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043551A1 true AR043551A1 (es) | 2005-08-03 |
Family
ID=32992599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100785A AR043551A1 (es) | 2003-03-14 | 2004-03-11 | Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbomoil]cicloalquil) propanoico como inhibidores de nep, composicion farmaceutica que lo comprende y usos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20040180941A1 (es) |
| EP (1) | EP1606272A1 (es) |
| JP (1) | JP3923512B2 (es) |
| KR (1) | KR20050110003A (es) |
| AP (1) | AP2005003393A0 (es) |
| AR (1) | AR043551A1 (es) |
| AU (1) | AU2004220269A1 (es) |
| BR (1) | BRPI0408377A (es) |
| CA (1) | CA2519072A1 (es) |
| CL (1) | CL2004000512A1 (es) |
| EA (1) | EA200501204A1 (es) |
| EC (1) | ECSP056017A (es) |
| HR (1) | HRP20050797A2 (es) |
| IS (1) | IS8003A (es) |
| MA (1) | MA27720A1 (es) |
| MX (1) | MXPA05009788A (es) |
| NL (1) | NL1025709C2 (es) |
| NO (1) | NO20054169L (es) |
| OA (1) | OA13039A (es) |
| PA (1) | PA8597401A1 (es) |
| PE (1) | PE20050310A1 (es) |
| TN (1) | TNSN05227A1 (es) |
| TW (1) | TW200504038A (es) |
| UY (1) | UY28226A1 (es) |
| WO (1) | WO2004080985A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007001348A (es) * | 2004-08-02 | 2008-03-11 | Bebaas Inc | Composiciones de vitamina b12. |
| WO2006027680A1 (en) * | 2004-09-10 | 2006-03-16 | Pfizer Limited | 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme |
| CN102861019B (zh) | 2004-12-24 | 2016-05-25 | 诺华股份有限公司 | 治疗或预防神经性疼痛的药物 |
| BRPI0615972A2 (pt) | 2005-07-29 | 2011-05-31 | Concert Pharmaceuticals Inc | composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto |
| US20070178141A1 (en) * | 2005-09-07 | 2007-08-02 | Bebaas, Inc. | Vitamin B12 compositions |
| US20130131007A1 (en) | 2005-09-07 | 2013-05-23 | Bebaas, Inc. | Vitamin b12 compositions |
| NZ572046A (en) * | 2006-03-20 | 2012-03-30 | Spinifex Pharm Pty Ltd | Method of treatment or prophylaxis inflammatory pain |
| EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| KR101177866B1 (ko) | 2011-03-24 | 2012-08-28 | 주식회사 케이엠더블유 | 케이블 접속 장치 |
| AU2019287549A1 (en) * | 2018-06-14 | 2021-01-28 | Astrazeneca Uk Limited | Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition |
| CN112955967A (zh) * | 2018-06-14 | 2021-06-11 | 阿斯利康(英国)有限公司 | 用cgmp特异性磷酸二酯酶5抑制剂医药组合物治疗勃起功能障碍的方法 |
| KR20220099991A (ko) * | 2019-11-08 | 2022-07-14 | 벨라 바이오사이언스 인크. | 여성 성기능 개선 또는 여성 성장애 치료를 위한 말초 작용 칸나비디올(cbd) 함유 조성물 및 이것의 용도 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2503059A (en) * | 1950-04-04 | Nxchj | ||
| US2599000A (en) * | 1950-09-02 | 1952-06-03 | Smith Kline French Lab | Nu, nu-disubstituted-beta-halo-alkylamines |
| US3238215A (en) * | 1963-10-17 | 1966-03-01 | Sterling Drug Inc | 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines |
| IT1066857B (it) * | 1965-12-15 | 1985-03-12 | Acraf | Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione |
| US3511836A (en) * | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
| NL175059C (nl) * | 1974-02-23 | Boehringer Mannheim Gmbh | Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten. | |
| US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
| US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
| FR2421888A1 (fr) * | 1978-02-06 | 1979-11-02 | Synthelabo | Amides d'alkylene-diamines et leur application en therapeutique |
| IT1094076B (it) * | 1978-04-18 | 1985-07-26 | Acraf | Cicloalchiltriazoli |
| JPS56110665A (en) * | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
| DE3528032A1 (de) * | 1985-08-05 | 1987-02-05 | Hoechst Ag | Verfahren zur herstellung 2-substituierter benzthiazole |
| PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| CA2189355A1 (en) * | 1995-03-01 | 1996-09-06 | Yasuo Onoda | Imidazoquinazoline derivatives |
| GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| EE200300469A (et) * | 2001-03-28 | 2004-02-16 | Pfizer Inc. | N-fenpropüültsüklopentüülasendatud glutaramiidi derivaadid kui NEP inhibiitorid FSAD puhul |
-
2004
- 2004-03-08 PA PA20048597401A patent/PA8597401A1/es unknown
- 2004-03-09 CA CA002519072A patent/CA2519072A1/en not_active Abandoned
- 2004-03-09 JP JP2006500337A patent/JP3923512B2/ja not_active Expired - Fee Related
- 2004-03-09 EP EP04718706A patent/EP1606272A1/en not_active Withdrawn
- 2004-03-09 WO PCT/IB2004/000822 patent/WO2004080985A1/en active Application Filing
- 2004-03-09 AP AP2005003393A patent/AP2005003393A0/xx unknown
- 2004-03-09 EA EA200501204A patent/EA200501204A1/ru unknown
- 2004-03-09 OA OA1200500261A patent/OA13039A/en unknown
- 2004-03-09 MX MXPA05009788A patent/MXPA05009788A/es unknown
- 2004-03-09 KR KR1020057017229A patent/KR20050110003A/ko not_active Application Discontinuation
- 2004-03-09 AU AU2004220269A patent/AU2004220269A1/en not_active Abandoned
- 2004-03-09 BR BRPI0408377-6A patent/BRPI0408377A/pt not_active IP Right Cessation
- 2004-03-10 PE PE2004000259A patent/PE20050310A1/es not_active Application Discontinuation
- 2004-03-11 UY UY28226A patent/UY28226A1/es not_active Application Discontinuation
- 2004-03-11 AR ARP040100785A patent/AR043551A1/es unknown
- 2004-03-12 CL CL200400512A patent/CL2004000512A1/es unknown
- 2004-03-12 TW TW093106666A patent/TW200504038A/zh unknown
- 2004-03-12 NL NL1025709A patent/NL1025709C2/nl not_active IP Right Cessation
- 2004-03-12 US US10/800,065 patent/US20040180941A1/en not_active Abandoned
-
2005
- 2005-08-29 IS IS8003A patent/IS8003A/is unknown
- 2005-09-07 NO NO20054169A patent/NO20054169L/no not_active Application Discontinuation
- 2005-09-12 HR HR20050797A patent/HRP20050797A2/hr not_active Application Discontinuation
- 2005-09-14 EC EC2005006017A patent/ECSP056017A/es unknown
- 2005-09-14 MA MA28498A patent/MA27720A1/fr unknown
- 2005-09-14 TN TNP2005000227A patent/TNSN05227A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004080985A1 (en) | 2004-09-23 |
| BRPI0408377A (pt) | 2006-03-21 |
| AP2005003393A0 (en) | 2005-09-30 |
| PE20050310A1 (es) | 2005-05-04 |
| JP3923512B2 (ja) | 2007-06-06 |
| MA27720A1 (fr) | 2006-01-02 |
| TNSN05227A1 (fr) | 2007-06-11 |
| NL1025709C2 (nl) | 2005-03-14 |
| US20040180941A1 (en) | 2004-09-16 |
| TW200504038A (en) | 2005-02-01 |
| HRP20050797A2 (en) | 2006-02-28 |
| CA2519072A1 (en) | 2004-09-23 |
| PA8597401A1 (es) | 2005-05-24 |
| NL1025709A1 (nl) | 2004-09-16 |
| OA13039A (en) | 2006-11-10 |
| CL2004000512A1 (es) | 2005-01-21 |
| JP2006526572A (ja) | 2006-11-24 |
| KR20050110003A (ko) | 2005-11-22 |
| ECSP056017A (es) | 2006-01-27 |
| EA200501204A1 (ru) | 2006-06-30 |
| UY28226A1 (es) | 2004-11-08 |
| NO20054169L (no) | 2005-12-07 |
| MXPA05009788A (es) | 2005-10-26 |
| NO20054169D0 (no) | 2005-09-07 |
| AU2004220269A1 (en) | 2004-09-23 |
| IS8003A (is) | 2005-08-29 |
| EP1606272A1 (en) | 2005-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043551A1 (es) | Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbomoil]cicloalquil) propanoico como inhibidores de nep, composicion farmaceutica que lo comprende y usos | |
| US7176238B1 (en) | Nitrostated and nitrosylated prostaglandins, compositions and methods of use | |
| TWI382836B (zh) | 二肽基肽酶ｉｖ之抑制劑 | |
| US20090054304A1 (en) | Heterocyclic modulators of tgr5 for treatment of disease | |
| RU2239633C2 (ru) | Применение селективных антагонистов альфа1b-адренергического рецептора для улучшения состояния при сексуальной дисфункции | |
| JP2015529239A (ja) | アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 | |
| US20080221161A1 (en) | Heterocyclic modulators of tgr5 for treatment of disease | |
| WO2005040135A1 (ja) | 抗ストレス薬およびその医薬用途 | |
| JP2009527551A (ja) | ２型糖尿病の治療用および避妊薬としてのシクロリグナンの使用 | |
| MA30514B1 (fr) | Nouveaux composes. | |
| DE60210805D1 (de) | Substituierte indolizinähnliche verbindungen und ihre verwendung | |
| NO318338B1 (no) | Anvendelse av farnesyl proteintransferaseinhibitorer for fremstilling av farmasoytiske sammensetninger for behandling av artropatier | |
| ATE427926T1 (de) | Cycloalkylaminderivate | |
| JP2016502978A (ja) | ＢＡＣＥ１の阻害剤としてのヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 | |
| UY29802A1 (es) | Análogos de la feniletilamina y su uso en el tratamiento del glaucoma | |
| ES2640638T3 (es) | Compuestos de fenil-hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituidos | |
| KR20220003555A (ko) | 안구 장애의 치료를 위한 화합물 및 방법 | |
| EP1534707A1 (en) | Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors | |
| WO2010014739A2 (en) | Heterocyclic modulators of tgr5 | |
| RU2279433C2 (ru) | Новое соединение для лечения импотенции | |
| AU2020259996A1 (en) | Compounds and methods for the treatment of ocular disorders | |
| CN110372663A (zh) | 含硫杂环化合物及其作为dpp4抑制剂衍生物的应用 | |
| WO2000078724A3 (en) | Imidazolinderivatives their preparation and their pharmaceutical use | |
| PE20081664A1 (es) | Derivados de azabicicloalcano, su preparacion y su aplicacion en terapeutica | |
| KR927003536A (ko) | 키누렌산 유도체, 그의 제조방법 및 이를 함유하는 약제학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FB | Suspension of granting procedure |